NeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021, at 2:00 pm ET. The company focuses on psilocybin's therapeutic potential for obesity and weight management, with two lead drug candidates: NEO-001 and NEO-002. The conference offers investors a live Q&A session, and a recorded version will be available post-event. Pre-registration is encouraged for attendance. For more details, visit www.virtualinvestorconferences.com.
- None.
- None.
VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -- NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) ("NeonMind" or the "Company"), based in Vancouver, focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, today announced that Robert Tessarolo, President and Chief Executive Officer, will present live at the KCSA Psychedelics Virtual Investor Conference.
DATE: October 14, 2021
TIME: 2:00 pm ET
REGISTRATION LINK: https://bit.ly/3kObcQO
The KCSA Psychedelics Virtual Investor Conference is a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
About NeonMind Biosciences
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind's lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs. For more information on NeonMind, go to www.NeonMindBiosciences.com
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neonmind-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-14th-301394912.html
SOURCE VirtualInvestorConferences.com
FAQ
What is the date and time for NeonMind's presentation at the KCSA Psychedelics Virtual Investor Conference?
What are the lead drug candidates of NeonMind Biosciences?
How can I participate in the KCSA Psychedelics Virtual Investor Conference?
What therapeutic area is NeonMind targeting with psilocybin?
Where can I find more information about NeonMind Biosciences?
